Company / R&D Expense
Tempest Therapeutics, Inc. R&D Expense History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$18.4M
FY2017
5-year range
$15.8M / $21.8M
FY2015-FY2017
Trend
-15.4%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $16M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2017.
Improved from $16M to $18M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2017, r&d expense decreased 15.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | $18.4M | -15.4% |
| FY2016 | $21.8M | +37.9% |
| FY2015 | $15.8M | - |
As of FY2017 · SEC 10-K · Updated Jun 28, 2026